These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28304215)

  • 1. Use of statistical and pharmacokinetic-pharmacodynamic modeling and simulation to improve decision-making: A section summary report of the trends and innovations in clinical trial statistics conference.
    Kimko H; Berry S; O'Kelly M; Mehrotra N; Hutmacher M; Sethuraman V
    J Biopharm Stat; 2017; 27(3):554-567. PubMed ID: 28304215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics/pharmacodynamics model-supported early drug development.
    Chen B; Dong JQ; Pan WJ; Ruiz A
    Curr Pharm Biotechnol; 2012 Jun; 13(7):1360-75. PubMed ID: 22201585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Confidence and Prediction Intervals for Pharmacometric Models.
    Kümmel A; Bonate PL; Dingemanse J; Krause A
    CPT Pharmacometrics Syst Pharmacol; 2018 Jun; 7(6):360-373. PubMed ID: 29388347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.
    Chien JY; Friedrich S; Heathman MA; de Alwis DP; Sinha V
    AAPS J; 2005 Oct; 7(3):E544-59. PubMed ID: 16353932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making.
    Gobburu JV; Marroum PJ
    Clin Pharmacokinet; 2001; 40(12):883-92. PubMed ID: 11735607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
    Gieschke R; Steimer JL
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How modeling and simulation have enhanced decision making in new drug development.
    Miller R; Ewy W; Corrigan BW; Ouellet D; Hermann D; Kowalski KG; Lockwood P; Koup JR; Donevan S; El-Kattan A; Li CS; Werth JL; Feltner DE; Lalonde RL
    J Pharmacokinet Pharmacodyn; 2005 Apr; 32(2):185-97. PubMed ID: 16283534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of modelling and simulation in Phase I drug development.
    Aarons L; Karlsson MO; Mentré F; Rombout F; Steimer JL; van Peer A;
    Eur J Pharm Sci; 2001 May; 13(2):115-22. PubMed ID: 11297895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of modeling and simulation in pediatric investigation plans.
    Manolis E; Osman TE; Herold R; Koenig F; Tomasi P; Vamvakas S; Saint Raymond A
    Paediatr Anaesth; 2011 Mar; 21(3):214-21. PubMed ID: 21244569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic/pharmacodynamic modeling in drug development.
    Sheiner LB; Steimer JL
    Annu Rev Pharmacol Toxicol; 2000; 40():67-95. PubMed ID: 10836128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro-In Vivo Correlation Using In Silico Modeling of Physiological Properties, Metabolites, and Intestinal Metabolism.
    Choi SM; Kang CY; Lee BJ; Park JB
    Curr Drug Metab; 2017; 18(11):973-982. PubMed ID: 29086683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reporting guidelines for population pharmacokinetic analyses.
    Dykstra K; Mehrotra N; Tornøe CW; Kastrissios H; Patel B; Al-Huniti N; Jadhav P; Wang Y; Byon W
    J Pharmacokinet Pharmacodyn; 2015 Jun; 42(3):301-14. PubMed ID: 25925797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling and simulation in the pharmaceutical industry--some reflections.
    Burman CF; Wiklund SJ
    Pharm Stat; 2011; 10(6):508-16. PubMed ID: 22162317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.
    Zhao P; Zhang L; Grillo JA; Liu Q; Bullock JM; Moon YJ; Song P; Brar SS; Madabushi R; Wu TC; Booth BP; Rahman NA; Reynolds KS; Gil Berglund E; Lesko LJ; Huang SM
    Clin Pharmacol Ther; 2011 Feb; 89(2):259-67. PubMed ID: 21191381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reporting guidelines for population pharmacokinetic analyses.
    Dykstra K; Mehrotra N; Tornøe CW; Kastrissios H; Patel B; Al-Huniti N; Jadhav P; Wang Y; Byon W
    J Clin Pharmacol; 2015 Aug; 55(8):875-87. PubMed ID: 26148467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fostering culture and optimizing organizational structure for implementing model-based drug development.
    Zhang L; Allerheiligen SR; Lalonde RL; Stanski DR; Pfister M
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):146S-150S. PubMed ID: 20881228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.
    Singh AP; Shin YG; Shah DK
    Pharm Res; 2015 Nov; 32(11):3508-25. PubMed ID: 25666843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visualization concepts to enhance quantitative decision making in drug development.
    Dykstra K; Pugh R; Krause A
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):130S-139S. PubMed ID: 20881226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mathematical modeling and simulation in animal health. Part I: Moving beyond pharmacokinetics.
    Riviere JE; Gabrielsson J; Fink M; Mochel J
    J Vet Pharmacol Ther; 2016 Jun; 39(3):213-23. PubMed ID: 26592724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.